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Meprins are zinc-dependent metalloproteinases that are
highly expressed in the brush-border membranes of both
the kidney and the intestines. Meprins are capable of
proteolytically degrading extracellular matrix proteins,
proteolytically processing bioactive proteins, and play a
role in inflammatory processes. In this study, the function
of meprin A in the acute kidney injury (AKI) model of cisplatin
nephrotoxicity was examined. Normal linear localization
of meprin A in the brush border membranes of proximal
tubules was altered in AKI. The meprin A a-subunit was
detected in the urine of both control and cisplatin-treated
mice. A cleaved product of the meprin A b-subunit,
undetected in the urine of control mice, was found to be
significantly increased in the urine during the progression
of cisplatin nephrotoxicity. The excretion of this b-fragment
was found to be before the rise in serum creatinine and
blood urea nitrogen (BUN) suggesting usefulness as a
biomarker for AKI. Pretreatment of mice with a meprin A
inhibitor afforded protection from cisplatin nephrotoxicity
as reflected by significant decreases in serum creatinine,
BUN, and the excretion of kidney injury molecule-1.
These decreases in serum and urine biomarkers were
accompanied by significant decreases in histologic markers
such as leukocyte infiltration and apoptosis. Meprin A
appears to be an important therapeutic target and urinary
excretion appears to be a potential biomarker of AKI.
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Meprins are zinc-dependent oligomeric metalloproteinases of
the ‘astacin’ family that are highly expressed at the brush-
border membranes of the kidney and intestines.1–4 Meprins
are expressed as an oligomeric complex made of a- and/or
b-subunits.1 The distribution of meprin subunits in adult
mice demonstrates that meprin A, the heterooligomeric
form comprised of both a and b-subunits, is the predomi-
nant form of meprin expressed abundantly in the apical
membranes of renal proximal tubules and comprises about
5% of the total brush-border membrane proteins in murine
kidneys.5–7 Both meprin a and meprin b-isoforms are initially
synthesized as membrane-spanning proteins but, during
biosynthesis, the transmembrane domain of the a-isoform is
proteolytically cleaved. Meprin b with its transmembrane
domain is anchored in the plasma membrane of the brush
border and associates with transmembrane domain-deficient
meprin a by disulfide linkages or noncovalent linkages.1,8
Thus meprin A, anchored to brush-border membranes only
by b-subunit, is a membrane-associated metalloendo-
peptidase of renal proximal tubules.
Our previous studies have demonstrated that meprin A
purified from the rat kidney cortex is the major protease
in the renal cortex capable of degrading components of the
extracellular matrix proteins including collagen IV, fibro-
nectin, laminin, and nidogen in vitro.5,9 Consistent with the
purified meprin from rat kidney, recombinant human
meprin was recently shown to degrade extracellular matrix
proteins in vitro.10,11 Meprins are also capable of proteo-
lytically processing bioactive peptides, cytokines, and peptide
hormones.2,3,12,13 Our recent studies demonstrated that
meprins can produce biologically active interleukin-1b from
its inactive proform,14 suggesting that meprins may play an
important role in inflammatory processes in addition to their
ability to degrade extracellular matrix components. Active
meprin A purified from rat kidney was found to be cytotoxic
in renal tubular epithelial cells in culture,15 further suggesting
a detrimental role of meprin A during renal injury.
Cisplatin nephrotoxicity is associated with damage in the
S3 segment of proximal tubules in the corticomedullary
junction that results in decline in renal function. Thus,
the manifestation of cisplatin-induced acute kidney injury
(AKI) is at the site where meprin A is predominantly
expressed. In addition, recent studies provide evidence that
cisplatin nephrotoxicity is associated with apoptosis, necro-
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sis, and inflammatory mechanisms.16–18 Therefore, this
study was performed to determine if meprin A plays a role
in cisplatin nephrotoxicity. We examined whether meprin A
(i) undergoes altered distribution and (ii) is excreted in the
urine in response to cisplatin-induced AKI injury, and
whether meprin A inhibition affords (i) protection from
cisplatin-induced cell death and inflammation; (ii) functional
and histologic protection from AKI; and (iii) prevention in
the shedding of kidney injury molecule (KIM), as the release
of KIM is dependent on a metalloproteinase.
RESULTS
Meprin A distribution in proximal tubules and altered
localization following cisplatin administration
Meprin A comprised of both a and b-subunits is expressed
abundantly in the apical brush border of the renal proximal
tubule epithelium. The distribution pattern of meprin A in
kidney sections was first examined by immunostaining using
meprin b polyclonal antibody. Tissue sections from normal
kidneys revealed a specific linear staining of meprin A in the
brush border or luminal surface of normal proximal tubules
in the corticomedullary junction. No staining was observed
in the luminal surface of distal tubules, glomeruli, and
collecting duct. Following 2 days of cisplatin treatment of
mice, staining for meprin A was altered and some staining
was observed in the cytoplasm and toward the basolateral
side in the proximal tubules but much of the staining
remained in the apical region. This positive staining was
scattered throughout the cytoplasm and basolateral plasma
membrane in a severely injured kidney after 3 days of
cisplatin treatment (Figure 1). These studies suggest that,
owing to enormous degradative potential, meprin A redis-
tribution may play a significant role in renal injury. Similar
altered staining in cisplatin injury was observed when kidney
sections were stained with meprin a antibody (data not
shown). Expression of meprin a and meprin b were
examined by Western blot using specific antibodies. The
protein levels of meprin expression in the kidney cortex did
not change significantly and remained more or less at the
same level in the kidney cortex in response to cisplatin (data
not shown).
Urinary excretion of meprin a and meprin b following
cisplatin injury
We also analyzed levels of meprin a and meprin b in urine
samples. Urine samples collected at 0, 4, 8, 16 h, 1, 2, and 3
days after cisplatin administration were immunoblotted with
specific anti-meprin a and anti-meprin b antibodies. Meprin
a was detected in urine samples of both untreated control
and cisplatin-treated mice. As meprin a is not directly
associated with membranes but only bound through meprin
b by disulfide bridges or by noncovalent interactions, it is
quite conceivable that meprin a is detected in the urine of
control mice. In contrast, there was no detectable meprin b in
the urine samples of untreated control mice. A cleaved form
of meprin b (B55 kDa) was detected in the urine samples
collected as early as 8 h after cisplatin treatment (Figure 2).
This suggests that membrane-associated meprin b
(B80 kDa) is somehow cleaved by an unknown protease at
initial stages of injury and the cleaved product released from
the membranes is excreted in the urine. The amount of
urinary meprin b cleaved fragment was increased markedly at
12 h and persisted at higher levels at 2 days of cisplatin
treatment.
Effect of meprin inhibitor actinonin on cisplatin-induced
morphological and functional renal damage
We assessed the role of meprin A in the pathogenesis of
cisplatin nephrotoxicity by measuring renal function and
kidney histology in mice treated with cisplatin in the presence
and absence of actinonin. We administered actinonin
intraperitoneally 1 h before the cisplatin injection. The effect
of actinonin on cisplatin-induced impairment of renal
function was determined by blood urea nitrogen (BUN)
and creatinine values at 1, 2, and 3 days. At 3 days after
cisplatin treatment, the mice showed marked deterioration in
renal function as reflected in increased levels of BUN and
serum creatinine. Intraperitoneal administration of 15 mg/kg
body weight (b.w.) actinonin significantly reduced cisplatin-
induced elevated levels of both BUN and serum creatinine
(Figure 3). As shown, actinonin alone did not effect either
BUN or creatinine values. We have previously shown that
15 mg/kg b.w. actinonin administered intraperitoneally
inhibited meprin A activity completely within 3 h in the
kidney cortex in vivo.15 We also examined the effect of
actinonin on cisplatin-induced histological damage. Histo-
logical assessment following cisplatin treatment revealed
severe tubular damage characterized by extensive loss of
tubular epithelial cells, loss of brush-border membranes,
tubular dilation, cellular desquamation, and proteinaceous
casts of the tubular cells. The meprin inhibitor actinonin
ameliorated most of the tubular injury (Figure 4). The
glomeruli maintained their normal structure upon cisplatin
treatment. Animals treated with cisplatin and actinonin
resulted in considerable improvement in histology as
reflected in significant protection from the severe tubular
injury (Figure 4). Semiquantitative evaluation of kidney
sections showed a tubular necrosis score of 0.0570.02 in
kidneys from mice treated with 20% ethanol in saline alone,
0.0470.04 in kidneys from mice treated with actinonin
alone, 3.470.5 in kidneys of 3 days cisplatin-treated mice,
and 0.470.08 in mice treated with 3 days cisplatin and
actinonin. The statistical differences were significant between
kidneys of cisplatin-treated mice and either 20% ethanol in
saline or cisplatin plus actinonin treated mice (n¼ 6,
Po0.005). These studies thus demonstrate that meprin
inhibition provides significant protection from cisplatin-
induced AKI.
To ensure that actinonin did not block the uptake of
cisplatin in the kidney, we isolated kidneys from mice (n¼ 4
in each group) following administration with cisplatin
(20 mg/kg b.w.) and cisplatin (20 mg/kg b.w.) plus actinonin
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(15 mg/kg b.w.). The kidney tissue was analyzed for platinum
content by Mayo Medical Lab (Rochester, MN, USA). The
results of this study revealed that meprin inhibitor actinonin
did not prevent uptake of cisplatin in the kidney (amount
of platinum in kidney tissue: control kidney; 0.0327
0.01 mg/g dry weight tissue, cisplatin; 34.675.6 mg/g dry
weight tissue, cisplatin plus actinonin; 35.274.5 mg/g dry
weight tissue).
a
b
Control ×10 Control ×20 Control ×40
1d CP ×40 2d CP ×40 3d CP ×40
Control
1d CP
2d CP
3d CP
Figure 1 | Time course of immunostaining of meprin A in kidneys of control mice and mice treated with cisplatin (CP). Mice were
injected intraperitoneally with saline vehicle or 20 mg/kg b.w. cisplatin in saline. Kidneys were harvested after 24, 48, and 72 h of cisplatin
administration. (a) Kidney sections prepared before and after cisplatin (CP) treatment were used to analyze meprin A distribution by
immunohistochemistry using polyclonal antibody to meprin b. (b) Meprin A distribution in a representative proximal tubule at higher
magnification before and after cisplatin (CP) treatment. The arrows show basolateral distribution of meprin A in addition to the apical
distribution in proximal tubules.
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Effect of meprin inhibitor actinonin on cisplatin-induced
renal cell apoptosis
As apoptosis has been implicated in tubule cell death in
response to cisplatin, we tested whether meprin inhibitor is
able to reduce cisplatin-induced renal cell apoptosis. The
TdT-mediated dUTP-biotin nick end labeling (TUNEL)
method to localize DNA fragmentation was performed to
detect apoptosis in situ. Cisplatin-treated mice displayed
extensive incidence of apoptotic cell death in kidney sections
compared with the saline-treated control mice. TUNEL-
positive nuclei were restricted mainly to the tubular epithelial
cells of the corticomedullary junction (Figure 5). Actinonin-
treated mice significantly attenuated cisplatin-induced apop-
totic response.
Effect of meprin inhibitor actinonin on cisplatin-induced
leukocyte infiltration
Recent studies show that cisplatin-induced AKI is associated
with infiltration of inflammatory cells into the kidney
cortex.16,17 Therefore, we performed naphthol AS-D chloro-
acetate staining and counted the number of esterase-positive
leukocytes in kidney tissue after treatment with cisplatin
alone or in combination with the meprin A inhibitor actino-
nin. Cisplatin treatment dramatically increased the number
of infiltrating leukocytes in the cortex and outer medulla
(2873, 10–12 fields/kidney). Following actinonin treatment,
these infiltrating neutrophils were significantly reduced
(471, 12 fields/kidney) (Figure 6).
Effect of actinonin on Kim-1 expression
Recent studies have demonstrated that both kidney
expression and urinary excretion of Kim-1 are considerably
increased in renal injury and can serve as a useful biomarker
for renal tubular injury.19,20 Previous studies demonstrated
that KIM is shed into the extracellular space by proteolytic
cleavage mediated by a metalloproteinase.21 As actinonin
inhibits the metalloendopeptidase meprin A, we explored
whether actinonin is capable of reducing urinary excretion of
Kim-1. As shown in Figure 7, Kim-1 excretion was markedly
increased in the urine of cisplatin-treated mice as reported
in a rat model of cisplatin nephrotoxicity.21 Actinonin was
quite effective in significantly reducing the levels of cisplatin-
induced Kim-1 excretion in the urine.
Meprin A-deficient mice afford protection from cisplatin
nephrotoxicity
Meprin A-deficient inbred strain of mice C3H/He lack more
than 90% of meprin A.22,23 Previous studies demonstrated
that in response to ischemia–reperfusion injury these mice
exhibited significantly less tubular necrosis, serum creatinine,
and BUN values compared with the normal C57 Bl/6 mice.23
We have examined whether these mice afford protection from
cisplatin-induced AKI. C3H/He mice ameliorated toxic renal
failure as reflected by improvement in histologic damage
(Figure 8). Cisplatin-induced changes in normal C57Bl/6
mice such as loss of brush-border membranes, sloughing
of tubular epithelial cells, dialation of tubules, and cast
formation were almost absent in kidneys from C3H/He mice
injected with cisplatin (Figure 8a). The amelioration of renal
failure was also reflected in significant decreases in BUN and
serum creatinine (Figure 8b).
DISCUSSION
This study supports a role for meprin A in renal tubular
epithelial cell injury in cisplatin nephrotoxicity. In normal
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Figure 2 | Urinary excretion of meprin a and meprin b before and
after treatment with cisplatin. (a) Western blot analysis of meprin a
in the urine. Urine samples were pooled from mice (n¼ 6) treated
with cisplatin or vehicle were normalized for proteins and loaded
into each lane. Proteins were probed with a specific anti-meprin a
antibody. (b) Western blot analysis of meprin b fragment in the
urine. Urine samples collected from mice (n¼ 6) were normalized
for protein amounts and subjected to Western blot analysis.
Proteins were probed with a specific anti-meprin b antibody. Purified
recombinant meprin b marker and molecular weight standards
are also shown. (c) Quantitative analysis by densitometry of a
representative meprin b fragment in the pooled urine from mice
(n¼ 6) treated with cisplatin. The meprin b fragment excreted at
24-h urine collection was considered at 100%.
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renal tissue, meprin A is localized on the apical brush-border
membranes of the proximal tubule.2,9 In response to cisplatin
injury, we demonstrate that meprin A’s linear localization in
the brush-border membranes is changed and is distributed
throughout the cytoplasm and some staining was observed
toward the underlying basement membrane of the proximal
tubules in the corticomedullary junction. Target substrates
for meprin A in the cytosol have not yet been identified that
may have detrimental effects within the cytosol. In a rat
model of ischemia–reperfusion injury, we have previously
demonstrated that meprin A undergoes redistribution from
the apical brush-border membranes to the cytoplasm to
reach the basolateral tubular basement membrane9 suggest-
ing that common mechanisms for meprin redistribution are
involved in toxic and ischemic renal injury. Considering the
enormous proteolytic potential of meprin A, the altered
location to places other than the apical membranes during
renal injury may be detrimental to the kidney. Meprins are
capable of degrading a wide variety of substrates ranging
from the major components of the basement membrane such
as collagen, laminin, fibronectin, and nidogen5,9,10,11 as well
as growth factors, protein kinases, and other bioactive
peptides.1,2,12,14 Previous studies in different inbred strains
of mice have demonstrated that meprin A is involved in renal
injury. It was shown that mice strains with low levels of
meprin A expression developed less acute renal failure
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Figure 3 | Effect of meprin inhibitor actinonin on cisplatin-induced loss of renal function as determined by BUN and serum creatinine.
Mice were injected intraperitoneally with vehicle 20% ethanol in saline or 15 mg/kg b.w. actinonin or 20 mg/kg b.w. cisplatin alone or cisplatin
with 15 mg/kg b.w. actinonin for 1 d (day), 2 d, and 3 d period. At the indicated times, BUN, n¼ 6, *Po0.005 and serum creatinine, n¼ 5,
*Po0.01 were determined using a diagnostic kit from Sigma or International Bio-Analytical Industries Inc. (Boca Raton, FL, USA).
Control Control + actinonin
3d CP 3d CP + actinonin
Figure 4 | Effect of actinonin on renal histology in cisplatin-induced AKI. PAS staining of kidney sections from mice treated with vehicle
20% ethanol/saline (Control), vehicle plus 15 mg/kg b.w. actinonin (controlþ actinonin), 20 mg/kg b.w. cisplatin (3 d (day) CP), and cisplatin
plus actinonin (3 d CPþ actinonin). Administration of actinonin alone has no effect on kidney histology.
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compared with those that express high levels of meprin A
when exposed to ischemia–reperfusion.22 Also, when meprin
A was added exogenously it was found to be cytotoxic in
cultured renal cells.15
Our studies demonstrate that a 55-kDa cleaved fragment
meprin b isoform undetected in the urine of normal mice is
significantly increased in cisplatin-treated mice. This increase
occurred much earlier than rise in the BUN and creatinine
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Figure 5 | Effect of actinonin on on apoptosis in cisplatin-induced AKI. TUNEL staining of kidney sections from mice treated with vehicle
20% ethanol/saline (Control), 20 mg/kg b.w. cisplatin (3 d (day) cisplatin), and cisplatinþ actinonin. Graph in the figure shows TUNEL-positive
cells counted in 10–12 high-power fields. *Po0.02 compare with vehicleþ cisplatin.
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Figure 6 | Effect of actinonin on leukocyte infiltration in kidney cortex in cisplatin-treated mice. Formalin-fixed and paraffin-embedded
kidney specimens (5 mm) from mice treated with vehicle 20% ethanol/saline (Control), 20 mg/kg b.w. cisplatin (3 days cisplatin), and
cisplatinþ actinonin, were stained using naphthol AS-D chloroacetate esterase staining kit (Kit No. 91C; Sigma) according to the manufacturer’s
instructions. Graph in the figure shows the esterase-positive leukocytes were counted in a blinded fashion, averaged from 10–12 fields/mouse
kidney and compared with different groups. *Po0.01 compare with vehicleþ cisplatin.
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values. Our results show that in response to cisplatin
treatment, urinary meprin b fragments were excreted as
early as 8 h after cisplatin administration and subsequently at
later times early low levels were significantly increased and
very high levels of meprin b were excreted in the urine after
2–3 days following cisplatin administration as shown in
Figure 2. Thus cellular and histological changes appear at
a time when very high levels of meprin b fragments are
excreted in the urine. Compared to the excretion of meprin
b fragments, maximum urinary excretion of a recently
discovered potential urinary marker KIM19,20 occurred after
1 day of cisplatin administration. Some excretion of KIM was
also detected in the urine of normal mice, whereas no meprin
b was detected in the urine of normal mice. As meprin
b under normal conditions is anchored to the membranes,
a proteolytic cleavage by unknown protease can produce the
55-kDa fragment. These studies suggest that meprin b can
be a potential biomarker of AKI. The excretion of meprin
a detected in the urine of normal mice increased marginally
in cisplatin nephrotoxicity. Consistent to our studies, meprin
a has been previously shown to be excreted in the urine of
normal mice.24 A recent study on proteomics in a sepsis
model has shown that meprin a is a potential biomarker of
this injury.25 The excretion of meprin a observed in the
normal mice was not changed significantly in the cisplatin-
treated mice. Thus, more studies are needed to explore
whether meprins can serve as an important biomarker in the
list of newly discovered potential biomarkers.26–29
The role of meprin A in cisplatin nephrotoxicity in mice
was examined using actinonin, a potent inhibitor of meprin
A. Actinonin, a naturally occurring hydroxamate found in
actinomycetes,30 has been proved to be a potent inhibitor of
meprin A.10,31 In addition, actinonin has been shown to have
antitumor activity and is able to inhibit peptide deformylase
and aminopeptidase N.32–34 Our studies demonstrate that
meprin inhibitor actinonin, when administered intraperito-
neally to the mice, provided significant protection from
cisplatin-induced AKI as reflected from the renal function
and morphological response. Actinonin strikingly prevented
structural damage inflicted by cisplatin and provided
protection from apoptosis, necrosis, and leukocyte infiltra-
tion. The protection from apoptosis and inflammation can
also arise from decreased renal injury promoted by the
meprin inhibitor. Previous studies have demonstrated
substantial intrarenal infiltration of leukocytes from circula-
tion during cisplatin nephrotoxicity.16,35–37 The leuko-
cytes can enhance tubular injuries via releasing oxidants
and proteinases.38 However, the underlying mechanisms by
which leukocytes in circulaton exit from the tubular
basement membrane into the renal tissue are not known.
Meprins are capable of degrading a wide variety of substrates
ranging from the major components of the basement
membrane such as collagen, laminin, fibronectin, and
nidogen.5,10,11 Thus, this degradative ability of meprin A
may cause damage to the tubular basement membrane that
may enable leukocytes to migrate across the basement
membrane. Recent studies have shown that regions of
basement membrane with low expression of collagen IV,
laminin, and nidogen can make the basement membrane
vulnerable to the exit of the emigrating leukocytes.39 Meprin
is also capable of producing biologically active proinflam-
matory cytokine interleukin-1b (IL-1b) from its proform,14
which may also help to propagate the inflammatory response.
The renal tubular epithelium is capable of producing
proinflammatory cytokines including IL-1b,30–42 and admini-
stration of IL-1 to rats has been shown to result in increased
neutrophil infiltration of the kidney.43 Chemokines, which
are chemotactic and immunomodulatory for leukocytes, are
upregulated by inflammatory cytokines such as IL-1 and
tumor necrosis factor-a.44 Future studies will reveal whether
meprin A is capable of producing active cytokines in vivo
during renal injury.
In summary, we demonstrate altered localization of
meprin A in renal proximal tubules in a mice model
of cisplatin nephrotoxicity. This suggests an important role
for meprin A in vivo in acute tubular injury due to its
enormous proteolytic ability to degrade extracellular matrix
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Figure 7 | Effect of actinonin on Kim-1 expression in kidney
cortex in cisplatin-treated mice. (a) Western blot analysis of Kim-1
expression in the urine. Urine samples collected before and after
cisplatin (CP) or CPþ actinonin treatment. Urine samples were
pooled from mice (n¼ 6–8) for each treatment and were normalized
for proteins and loaded into each lane. Proteins were probed with a
specific anti-Kim-1 antibody. Graph in lower panel shows quantitative
analysis of representative Kim-1 protein levels by densitometry.
CP (empty bars) and CPþ actinonin (filled bars).
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components as well as in processing of inflammatory
cytokines. An early urinary excretion of cleaved fragment
of meprin b that significantly increased before the rise in
serum creatinine and BUN implies that meprin b may be
a potential biomarker of AKI. However, more studies are
needed to confirm this important observation using
other models of AKI. Actinonin, a potent meprin A inhibitor,
was effective in ameliorating cisplatin-induced AKI and
preventing cisplatin-induced leukocyte infiltration, apop-
tosis, and urinary Kim-1 excretion. Consistent with the
studies with meprin A inhibitor, inbred strain of meprin
A-deficient mice also ameliorated cisplatin-induced AKI
as reflected by improvement in histologic damage and
renal function.
MATERIALS AND METHODS
Animals and induction of cisplatin-induced acute renal
failure
Ten-week-old C57BL/6 mice weighing 20–25 g were obtained from
the Jackson Laboratories (Bar Harbor, ME, USA) and maintained on
a standard diet with free access to water. Animal protocol to develop
a mice model of cisplatin-induced AKI complied with the standards
for care and use of animal subjects, and was approved by the
Institutional Animal Care and Use Committee and Institutional
Safety Committee. Mice (n¼ 6) were given a single intraperitoneal
injection of cisplatin (20 mg/kg b.w.) or actinonin (15 mg/kg b.w.)
1 h before the injection of cisplatin (20 mg/kg b.w.). Control animals
(n¼ 6, in each group) were administered either 20% ethanol (50 ml/
mice) in saline or actinonin (15 mg/kg b.w.) in 20% ethanol in
saline. Animals were housed in metabolic cages and timed urine
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Figure 8 | Meprin A-deficient mice afford protection from cisplatin nephrotoxicity. (a) Effect on renal histology in C3H/He meprin
A-deficient mice in response to cisplatin treatment. PAS staining of kidney sections from mice (C57 Bl strain) treated with vehicle saline
(Control, C57 Bl), 20 mg/kg b.w. cisplatin in saline (3 d (day) CP, C57 Bl), meprin-deficient mice (C3H/He) treated with saline (Control C3H/He),
and meprin-deficient mice treated with 20 mg/kg b.w. cisplatin in saline (3 d CP, C3H/He). (b) Renal function in meprin-deficient mice
(C3H/He) in response to cisplatin. Mice were injected intraperitoneally with vehicle saline or 20 mg/kg b.w. cisplatin for 3 d period. At the
indicated times, BUN, n¼ 6, *Po0.02 compared with 3 d CP (C57 Bl) and serum creatinine, n¼ 6, *Po0.01 compared with 3 d CP (C57 Bl)
were determined using a diagnostic kit from International Bio-Analytical Industries Inc. (Boca Raton, FL, USA).
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collections were made at 4, 8, 16 h, 1, 2, and 3 days following
cisplatin treatment. Kidneys were harvested at 1, 2, and 3 days for
histology, immunohistochemistry, in situ detection of apoptosis by
TUNEL staining, leukocyte infiltration, immunoblot for meprins.
Blood was collected for BUN and serum creatinine level determina-
tions. BUN and creatineine were determined using a diagnostic
kit from Sigma or International Bio-Analytical Industries Inc.
(Boca Raton, FL, USA).
Histology and immunohistochemistry
Kidney tissue was fixed in phosphate-buffered 4% formalin (pH 7.4)
for 24 h and then embedded in paraffin. Sections were cut into
5-mm-thick slices and used for staining with periodic acid-Schiff
stain (PAS) and immunohistochemistry for meprin A. Tubular
injury including brush-border loss, tubule dilatation, tubule
necrosis, and tubule cast formation after cisplatin injection was
evaluated in PAS-stained sections using a semiquantitative scale
ranging from 0 to 4 in which no injury (0), mild (1), moderate (2),
severe (3), and to very severe (4) were assigned. The slides were
evaluated and scored in a blinded fashion to the treatment by a renal
pathologist. For immunohistochemical localization of meprin A,
tissue sections were deparaffinized, incubated with a 1:200 goat
polyclonal meprin b primary antibody (Santa Cruz, CA, USA, sc-
23491) or rabbit polyclonal meprin a from Dr Judith Bond, washed
in phosphate-buffered saline and incubated with donkey anti-goat
or goat anti-rabbit secondary antibodies, respectively, conjugated
with horseradish peroxidase. The sections were then incubated at
room temperature with a mixture of 0.05% diaminobenzidine
containing 0.01% H2O2 and counterstained with Mayer’s hematox-
ylin. Buffer solutions were substituted for the primary antibody for
the negative control.
Evaluation of leukocyte infiltration
Neutrophil infiltration was evaluated using naphthol AS-D chlor-
oacetate esterase staining of infiltrating neutrophils in the cortex.
Briefly, formalin-fixed and paraffin-embedded kidney specimens
(5mm) were stained using naphthol AS-D chloroacetate esterase
staining kit (Kit No. 91C; Sigma) according to the manufacturer’s
instructions. The esterase-positive neutrophil infiltration cells were
counted in a blinded fashion by the renal pathologist and averaged
from 7 to 10 fields/mouse kidney.
In situ detection of apoptosis
Apoptotic cells in kidney were detected in situ in kidney sections by
the TUNEL method using a TdT-FragEL DNA fragmentation
detection kit (Cat No. Q1A33, Calbiochem, San Diego, CA, USA)
following the manufacturer’s protocol. Kidney sections were
deparaffinized, rehydrated, and the number of TUNEL-positive
nuclei was counted from randomly selected 10–12 fields/section and
three sections per kidney at 200-fold magnification.
Western blot analysis of urine meprin a, meprin b, and urine
Kim-1
Urine samples were collected either directly from the bladder when
kidneys were harvested or by spontaneous voiding or by using the
metabolic cages during a 24 h period of housing. Urine samples were
kept on ice and 5 mM ethylenediaminetetraacetic acid. Urine samples
were spun at 16 000 g for 10 min to remove sediment and aliquots
were dialyzed against 20 mM Tris/Cl pH 7.5. Urine samples
normalized to protein concentration were subjected to sodium
dodecyl sulfate-polyacrylamide gel elctrophoresis using 4–12%
NuPAGE Bis/Tris gels (Invitrogen, Carlsbad, CA, USA). The proteins
separated on the gel were electrophoretically transferred to a
Transblot membrane (Bio-Rad, Hercules, CA, USA), probed with
specific antibodies to meprin a, meprin b, and Kim-1, and detected
using the enhanced chemiluminescence system as described
previously.18
Meprin a and meprin b expression in kidney tissue
The expression of meprin a and meprin b was determined in the
kidney cortex before or after treatment of mice with cisplatin.
Kidney cortices were homogenized in 20 mM N-2-hydroxyethyl-
piperazine-N0-2-ethanesulfonic acid/Na, pH 7.2, containing 0.5%
NP40, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.5 mM phenyl-
methylsulfonyl flouride or 4(2-aminoethyl) benzene sulfonyl
fluoride (AEBSF), 1 protease inhibitor cocktail Sigma P-8340.
Kidney homogenates were centrifuged and supernatants (50 mg
protein) were subjected to Western blot analysis and probed with
specific antibodies to meprin a and meprin b. Protein concentration
was measured using a Bradford dye-binding assay (Bio Rad).
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